1 0

    FDA Exclusivity Summary for NDA 217225 – IZERVAY (Avacincaptad Pegol)

    FDA Exclusivity Summary for NDA 217225 – IZERVAY (Avacincaptad Pegol)

    $69.00 USD
    $69.00 USD
    Sale Sold out
    Original Request: Please provide a copy of the “Exclusivity Summary” included in the Approval Package for NDA 217225 for IZERVAY (avacincaptad pegol sodium), approved on August 4, 2023. Please provide the responsive items electronically by email if possible.
    Tags: Pharma, NDA, 2023

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details